Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
Oncology Letters
Join Editorial Board Propose a Special Issue
Print ISSN: 1792-1074 Online ISSN: 1792-1082
Journal Cover
June-2018 Volume 15 Issue 6

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
June-2018 Volume 15 Issue 6

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Article Open Access

FPOA induces apoptosis in HeLa human cervical cancer cells through a caspase‑mediated pathway

  • Authors:
    • Xin Li
    • Tolgor Bau
    • Haiying Bao
  • View Affiliations / Copyright

    Affiliations: Engineering Research Centre of Edible and Medicinal Fungi, Ministry of Education, Jilin Agricultural University, Changchun, Jilin 130118, P.R. China
    Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
  • Pages: 8357-8362
    |
    Published online on: March 29, 2018
       https://doi.org/10.3892/ol.2018.8380
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:



Abstract

In the present study, the triterpenoid 3‑acetoxylanosta‑8,24‑dien‑21‑oic acid (FPOA) was extracted from Fomitopsis pinicola. The aim of the present was to elucidate the mechanism of action of FPOA in HeLa cervical cancer cells. Cell viability was examined using an MTT assay and the morphological detection of apoptosis was conducted using DAPI staining. The rate of apoptosis was examined via Annexin V‑FITC/PI double staining and the expression levels of apoptosis‑associated proteins were determined by western blot analysis. FPOA was observed to inhibit HeLa cell proliferation, with IC50 values of 25.28, 15.30 and 11.79 µg/ml at 24, 48 and 72 h, respectively. Typical apoptotic bodies were observed in the HeLa cells following treatment with FPOA, as revealed by DAPI staining. The percentage of apoptotic cells was 3.00, 3.12, 6.18 and 32.28% following treatment with FPOA at concentrations of 0, 7.5, 15 and 30 µg/ml, respectively. Western blot analysis showed that caspase‑3 and ‑9 were cleaved more frequently after treatment with FPOA. Furthermore, the expression of Bax was increased but Bcl‑2 expression was decreased after treatment with FPOA. These results suggest that FPOA can induce HeLa cell apoptosis through a caspase‑mediated pathway.

Introduction

Cervical cancer is the most common type of gynecological cancer. There are ~500,000 newly diagnosed cases, and >250,000 associated deaths worldwide each year (1). The incidence of cervical cancer has decreased in developed countries, while continuing to increase in developing countries (2). The currently available treatment routes for cancer include surgery, radiotherapy and chemotherapy, but the efficiency of these treatments is low and they involve various adverse effects (3). Therefore, we need to develop new low-toxicity drugs for cancer treatment.

Fomitopsis pinicola (F. pinicola; Sw. Ex Fr.) Karst is one of the most common wood-rooting fungi in the northern hemisphere (4). It is widely distributed in Japan, Korea, China and Sweden (5). F. pinicola has a long history of medicinal use for the treatment of poor leg circulation in the elderly in Northeast China, and has been used for diabetes in Japan (6). F. pinicola is a non-toxic natural product that is becoming increasingly more attractive in academia. The extracts of F. pinicola have numerous pharmacological effects, including anti-inflammatory, antimicrobial, antifungal and anti-obesity properties (7–10). Wu et al (11), reported that the ethanol extract of F. pinicola could induce apoptosis in A549, HCT-116 and MDA-MB-231 cells, and inhibit SW180 cell growth in vivo. Chemical analysis showed that there were no ergosterol, ergosterol derivatives or lanostane triterpenes in the F. pinicola extract (12,13).

We isolated the triterpenoid 3-acetoxylanosta-8,24-dien-21-oic acid (FPOA; Fig. 1) from the fruiting body of F. pinicola, and determined that it was the primary active ingredient (14). In this study, we aimed to elucidate whether FPOA could inhibit the growth of HeLa cells, as well as to investigate its underlying mechanisms.

Figure 1.

Structure of 3-acetoxylanosta-8,24-dien-21-oic acid.

Materials and methods

Materials

The fruiting bodies were obtained in Changbai Mountain, Jilin Province, P.R.China. The 3-acetoxylanosta-8,24-dien-21-oic acid (FPOA) was extracted from the fruiting bodies of Fomitopsis pinicola. The fruiting bodies were extracted with ethanol and separated by silica gel column, elution with a mixture of petroleum ether and ethyl acetate to get FPOA. The purity of FPOA was >95%, as detected via HPLC. Antibodies against caspase-3, −9, Bcl-2, PARP and Bax were purchased from Cell Signaling Technology, Inc., (Danvers, MA, USA). β-actin was obtained from Wuhan Sanying Biotechnology, (Wuhan, China). BCA protein assay kit was purchased from Beijing Leagene Biotech, Co., Ltd., (Beijing, China). An Annexin V-FITC Apoptosis Detection kit was obtained from Tianjin Sungene Biotech Co., Ltd., (Tianjin, China). MTT and all other reagents were obtained from Sigma-Aldrich; Merck KGaA (Darmstadt, Germany).

Cell culture

Human cervical cancer HeLa cells were obtained from the Shanghai Institute of Cell Biology, Chinese Academy of Sciences (Shanghai, China). The HeLa cells were cultured in RPMI-1640 medium (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% fetal bovine serum (Sijiqing; Zhejiang Tianhang Biotech Co., Ltd., Huzhou, China) and 1% penicillin-streptomycin.

MTT assay

Cell viability was evaluated using an MTT assay, as previously described (15). Briefly, HeLa cells were seeded into 96-well plates with 4,500 cells/well and treated with different concentrations of FPOA (12.5, 25, 50, 100 and 200 µg/ml). After incubation for 20, 44 and 68 h, 37°C, 10 µl MTT (5 mg/ml) was added to each well and then incubated for another 4 h, 37°C. Subsequently, dimethyl sulfoxide (100 µl) was added to each well and the plates were agitated for 10 min. The absorbance was read at a wavelength of 570 nm using a microplate reader. The inhibitory concentration 50% (IC50) was defined as the concentration of experimental compound required to inhibited 50% cell proliferation, as compared with the untreated cells (16). The IC50 was calculated with GraphPad Prism v5.0 (GraphPad Software, Inc., La Jolla, CA, USA).

DAPI staining

DAPI staining was performed as previously described (17). Briefly, HeLa cells were seeded into 6-well plates with 140,000 cells/well and treated with FPOA for 24 h. The cells were fixed with 4% polyoxymethylene at room temperature for 10 min. The coverslips were equilibrated in PBS, following which 300 µl DAPI (300 nM) staining solution was added to the coverslips and incubated for 5 min at room temperature. The coverslips were rinsed two times in PBS and viewed using a fluorescence microscope (Nikon TE-2000 U; Nikon Corporation, Tokyo, Japan). The normal cell nuclei were faint staining (cells were alive). The apoptotic cell nuclei were brightness (18).

Apoptosis assay

Annexin V-FITC/PI staining was performed, followed by flow cytometry as previously described (15). Briefly, HeLa cells were seeded into 6-well plates with 140,000 cells/well and treated with FPOA for 24 h, after which the cells were collected and washed with cold PBS. Then, the cells were resuspended in 300 µl binding buffer. The cells were incubated with 5 µl Annexin V-FITC and 5 µl propidium iodide (PI) in the dark for 15 min at room temperature. Finally, the cells were analyzed via flow cytometry (BD FASCCalibur; BD Biosciences, Franklin Lakes, NJ, USA). The total percentage of apoptotic cells was defined as the sum of both early apoptosis (annexin V-FITC positive, PI negative) and late apoptosis (annexin V-FITC PI positive), top and bottom right quadrants in a flow cytometric dot plots, respectively (19). For each sample, 10,000 events were collected and analyzed by CellQuest™ Pro (v6.0) software (BD Biosciences).

ROS detection

ROS generation was assessed as previously described (20). Briefly, HeLa cells were seeded into 6-well plates with 140,000 cells/well and treated with FPOA for 24 h. Following this, HeLa cells were incubated with non-fluorescent probe 2′,7′-dichlorofluorescein diacetate (DCFH-DA) for 20 min at 37°C, and then cells were washed two times with medium without serum. ROS was examined by fluorescence microscopy or flow cytometry.

Western blot analysis

HeLa cells were seeded into 6-well plates with 140,000 cells/well and treated with FPOA for 24 h, following which the cells were harvested and lysed on ice with RIPA buffer (150 mM NaCl, 1% Triton-X-100, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris-HCl, pH 7.4) for 30 min. After centrifugation at 13,000 × g for 15 min, the protein concentration was determined using a BCA protein assay kit. Then, 20 µg cell lysate proteins were loaded onto 12% SDS-polyacrylamide gels, resolved via electrophoresis and then electrophoretically transferred to a polyvinylidene difluoride membrane. The membrane was blocked with 5% (w/v) non-fat milk for 1 h. After blocking, the membrane was incubated overnight at 4°C with primary antibodies: caspase-3 (cat. no. 9662, 1:1,000 dilution), caspase-9 (cat. no. 9508, 1:1,000 dilution), Bcl-2 (cat. no. 2876, 1:1,000 dilution), PARP (cat. no. 9542, 1:1,000 dilution) and Bax (cat. no. 2772, 1:1,000 dilution) supplied by Wuhan Sanying Biotechnology. β-actin (20536-1-AP, 1:1,000 dilution; Wuhan Sanying Biotechnology), was also used. Membranes were then washed twice with PBST and incubated with horseradish peroxidase (HRP)-conjugated anti-rabbit (cat. no. IH-0011, 1:5,000 dilution) and anti-mouse antibodies (cat. no. IH-0031, 1:5,000 dilution) supplied by Dingguo Changsheng Biotechnology, (Beijing, China) at room temperature for 1 h. Then the membranes were then washed twice with PBST at room temperature. Western blot bands were detected using Odyssey v1.2 software.

Statistical analysis

Results are expressed as the mean ± SD. Statistical comparisons were evaluated by SPSS v21.0 (IBM SPSS, Armonk, NY, USA) using the Student's t-test or one-way analysis of variance with Tukey's post hoc test. P<0.05 was considered to indicate a statistically significant difference.

Results

FPOA inhibits cell proliferation

We investigated the growth inhibitory effect of FPOA on HeLa cells using an MTT assay. As shown in Fig. 2, FPOA could inhibit the proliferation of HeLa cells in a dose- and time-dependent manner. IC50 values of 25.28, 15.30 and 11.79 µg/ml were calculated at 24, 48 and 72 h, respectively.

Figure 2.

Cytotoxicity of FPOA on HeLa cells. HeLa cells were seeded in 96-well plates and incubated with different concentrations of FPOA for 24, 48 and 72 h. Cell viability was determined using an MTT assay. Values are presented as the mean + SD of three experiments. *P<0.05 vs. control group. FPOA, 3-acetoxylanosta-8,24-dien-21-oic acid. The inhibitory concentration 50% (IC50) in µM is defined as the concentration of experimental compound required to inhibited 50% of the conversion of MTS to formazan, as compared with the absorbance produced by untreated cells after 16 h of incubation.

FPOA induces the apoptosis of HeLa cells

In order to elucidate whether FPOA induces apoptosis, DAPI staining was performed. As shown in Fig. 3, numerous apoptotic bodies containing unclear fragments were observed following FPOA treatment, but comparatively few were present in the control group. These results indicated that FPOA could induce the apoptosis of HeLa cells.

Figure 3.

Apoptosis of HeLa cells induced by FPOA. HeLa cells were incubated with various concentrations of FPOA for 24 h and then stained with DAPI. There were few apoptotic cells in control group. However, apoptotic cells appeared after 24 h of treatment with FPOA (15 and 30 µg/ml). (A) Fluorescence microscopy images of DAPI stained cells (magnification, ×100). The normal cell nuclei were faint staining (cells were alive). The apoptotic cell nuclei were brightness. Scale bar: 100 µm. (B) The number of cells with brightness was quantified from 3 wells and 5 vision fields from each well was presented. The graphs represent the mean ± SD. *P<0.05 vs. control group. Each experiment was repeated three times. FPOA, 3-acetoxylanosta-8,24-dien-21-oic acid.

Furthermore, in order to quantify the rate of apoptosis, Annexin V-FITC/PI staining was performed. As shown in Fig. 4, the percentage of apoptotic cells was 3.00, 3.12, 6.18 and 32.28% following treatment with 0, 7.5, 15 and 30 µg/ml FPOA, respectively.

Figure 4.

Annexin V-FITC/PI staining of HeLa cells incubated with FPOA. (A) HeLa cells were incubated with various concentrations of FPOA (7.5, 15 and 30 µg/ml) for 24 h. Cells were then subjected to Annexin V-FITC/PI staining and analyzed via flow cytometry. (B) The total percentage of apoptotic cells were stained with annexin V-FITC defined as the sum of both early apoptosis and late apoptosis (white bars). Cells that were stained only with PI, due to the loss of plasma membrane integrity, were considered necrotic cells (black bars). The data shown in the bar charts represent the mean ± SD of three independent experiments. *P<0.05 vs. control group. FPOA, 3-acetoxylanosta-8,24-dien-21-oic acid; FITC, fluorescein isothiocyanate; PI, propidium iodide.

FPOA induces ROS in HeLa cells

In order to test whether mitochondria play a role in FPOA-induced apoptosis, we performed ROS generation assays. As shown in Fig. 5, FPOA could increase ROS production in a dose-dependent manner.

Figure 5.

Measurement of ROS. The generation of ROS was assessed using non-fluorescent probe 2′,7′-dichlorofluorescein diacetate (DCFH-DA) staining. (A) Fluorescence intensity was observed using a fluorescence microscope. DCF fluorescence intensity is an indication of the amount of ROS present in the cells. Up: Phase morphology; Down: DCFH-DA staining. Scale Bar: 50 µm. (B) Then the cells were collected and fluorescence was measured by flow cytometry. *P<0.05 vs. control. Each experiment was repeated three times and similar results were obtained. ROS, reactive oxygen species.

Induction of apoptosis via the caspase cysteine protease familyIt is known that the cysteine protease family is an integral part of the apoptotic signaling cascade. As shown in Fig. 6, the levels of cleaved caspase-9 and caspase-3 were increased following treatment with FPOA. PARP is a substrate of caspase-3 (21). After treatment with FPOA, PARP was hydrolyzed to an 89-kDa fragment, corresponding to the activation of caspase-3.

Figure 6.

HeLa cells were incubated with various concentrations of FPOA for 24 h. HeLa cells were incubated with different concentrations of FPOA for 24 h, lysed, and resolved via 12% SDS-PAGE, following which western blotting was carried out to detect the activation and expression of caspase-9, −3 and poly (ADP-ribose) polymerase. The results are representative of three separate experiments, and β-actin was used as the internal control. FPOA, 3-acetoxylanosta-8,24-dien-21-oic acid.

FPOA regulates the expression of Bcl-2 family proteins

Bcl-2 family members are critical regulators of the apoptotic cascade (15). We further investigated the effect of FPOA on the Bcl-2 protein family. As shown in Fig. 7, the expression of Bcl-2 was decreased while the expression of Bax was increased following treatment with FPOA. These results suggested that FPOA induced apoptosis by regulating the ratio of Bcl-2 to Bax.

Figure 7.

Alterations in the levels of Bcl-2 family proteins in HeLa cells incubated with FPOA. HeLa cells were incubated with different concentrations of FPOA (7.5, 15 and 30 µg/ml) for 24 h, lysed, and then whole cell lysates were subjected to western blot analysis to examine the expression of Bcl-2 and Bax. β-actin was used as the internal control. Each experiment was repeated 3 times and similar results were obtained. The results are representative of three separate experiments, and β-actin was used as the internal control. FPOA, 3-acetoxylanosta-8,24-dien-21-oic acid.

Discussion

In a previous study, the fungal extracts exhibited anti-cancer effects in multiple tumor types (11). FPOA, isolated from the fruiting body of F. pinicola, was determined to be the main active ingredient (14). Here, we studied the anticancer activity of FPOA, and found that FPOA could inhibit the proliferation of HeLa cells in a dose-dependent manner. Morphological examination revealed that HeLa cells exhibited cellular alterations after treatment with FPOA. Chromatin condensation, a change typically observed during apoptosis, was revealed by DAPI staining. In addition, the Annexin V-FITC/PI double-staining assay confirmed the apoptosis induced by FPOA (Fig. 4). The results verified FPOA exerted anticancer activity through inducing apoptosis.

Apoptosis is an important mechanism for regulating the development of organisms, the renewal of cells and the stability of the intracellular environment (22,23). At present, there are two pathways involved in the apoptosis cascade, including the mitochondrial-mediated intrinsic pathway, and the endoplasmic reticulum pathway; these pathways are interlinked and interact to promote apoptosis (24). The Bax/Bcl-2 protein family is involved in the mitochondrial-mediated intrinsic pathway. Specifically, Bcl-2 and Bax can regulate the permeability of mitochondrial membranes. When the Bax/Bcl-2 ratio increases, the permeability of the mitochondrial membrane increases, which induces apoptosis. We detected the expression of certain Bcl-2 family members via western blotting; the data suggested that FPOA treatment leads to elevated Bax levels, accompanied by a decrease in Bcl-2 levels (Fig. 7).

Activation of the caspase protease family has an important role in the apoptosis regulated by the Bcl-2 family. Caspases are produced as inactive zymogens and undergo proteolytic activation during apoptosis. Caspase-9 is a regulator in the caspase cascade reaction and is involved in the mitochondrial-mediated intrinsic pathway; and caspase-3 is a primary effector that triggers the initiation of apoptosis (25). Our results indicated that FPOA treatment induced the proteolytic activation of caspase-9 and −3 in a dose-dependent manner (Fig. 6). PARP has a protective effect on DNA; as a substrate for caspase-3 involved in apoptosis, PARP is cleaved by caspase-3, leading to DNA damage and apoptosis. We found that FPOA also resulted in the cleavage of 116 kDa PARP into an 89-kDa fragment in HeLa cells (Fig. 6). Taken together, our data suggested that FPOA induced the mitochondrial-mediated apoptosis of HeLa cells by activating the caspase cascade.

In conclusion, this study demonstrated that FPOA could inhibit the proliferation of HeLa cells by inducing apoptosis. Furthermore, our results demonstrated that FPOA induces apoptosis in HeLa cells via the mitochondrial-mediated intrinsic pathway. The present results suggested that FPOA could be a potential anticancer agent for human cervical cancer.

Acknowledgements

The authors would like to thank Professor Dayun Sui from the Department of Pharmacology, School of Pharmaceutical Sciences, Jilin University (Changchun, China) for providing technical guidance. The technical assistance of Professor Huali Xu, Dr Yuchen Wang and Dr Zeyuan Lu from the Department of Pharmacology, School of Pharmaceutical Sciences, Jilin University (Changchun, China) is also acknowledged.

Funding

The present study was supported by the Science and Technology Development Plan Project of Jilin Province, China (grant no. 20150311016YY), and the National Natural Science Foundation of China (grant no. 31270088).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

TB and HB conceived and designed the study. XL performed the experiments. XL and HB wrote the paper. TB, HB and XL reviewed and edited the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1 

Bayu H, Berhe Y, Mulat A and Alemu A: Cervical cancer screening service uptake and associated factors among age eligible women in mekelle zone, northern ethiopia, 2015: A community based study using health belief model. PLoS One. 11:e01499082016. View Article : Google Scholar : PubMed/NCBI

2 

Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI

3 

Cragg GM and Newman DJ: Plants as a source of anti-cancer agents. J Ethnopharmacol. 100:72–79. 2005. View Article : Google Scholar : PubMed/NCBI

4 

Gilbertson RL and Ryvarden L: North american polypores, vol. 2, megasporoporia-wrightoporia. Mycologia. 81:437–885. 1987.

5 

Ying JZ MX, Ma QM, Zong YC and Wen HA: Illustrated handbook for medicinal fungi from China. Beijing: Science Press. 120, 128, 172; pp. 2181987

6 

Usui T SK, Satoh H, Iwasaki Y and Mizuno T: Studies on host mediated antitumor polysaccharides. Part V. Chemical structure and antitumor activity of a water-soluble Glucan isolated from Tsugasarunokoshikake, the fruit body of Fomitopsis pinicola. Shizuoka Daigaku Nogakubu Kenkyu Hokoku. 29–40. 1982.

7 

Yoshikawa K, Inoue M, Matsumoto Y, Sakakibara C, Miyataka H, Matsumoto H and Arihara S: Lanostane triterpenoids and triterpene glycosides from the fruit body of Fomitopsis pinicola and their inhibitory activity against COX-1 and COX-2. J Nat Prod. 68:69–73. 2005. View Article : Google Scholar : PubMed/NCBI

8 

Keller AC, Maillard MP and Hostettmann K: Antimicrobial steroids from the fungus Fomitopsis pinicola. Phytochemistry. 41:1041–1046. 1996. View Article : Google Scholar : PubMed/NCBI

9 

Guler P, Akata I and Kutluer F: Antifungal activities of fomitopsis pinicola (Sw.:Fr) Karst and Lactarius vellereus (Pers.) Fr. African J Biotechnol. 8:3811–3813. 2009.

10 

Jung HY, Ji Y, Kim NR, Kim DY, Kim KT and Choi BH: A fomitopsis pinicola jeseng formulation has an antiobesity effect and protects against hepatic steatosis in mice with high-fat diet-induced obesity. Evid Based Complement Alternat Med. 2016:73124722016. View Article : Google Scholar : PubMed/NCBI

11 

Wu HT, Lu FH, Su YC, Ou HY, Hung HC, Wu JS, Yang YC and Chang CJ: In vivo and in vitro anti-tumor effects of fungal extracts. Molecules. 19:2546–2556. 2014. View Article : Google Scholar : PubMed/NCBI

12 

Rösecke J and König WA: Steroids from the fungus Fomitopsis pinicola. Phytochemistry. 52:1621–1627. 1999. View Article : Google Scholar

13 

Rosecke J and König WA: Constituents of various wood-rotting basidiomycetes. Phytochemistry. 54:603–610. 2000. View Article : Google Scholar : PubMed/NCBI

14 

Ren G, Liu XY, Zhu HK, Yang SZ and Fu CX: Evaluation of cytotoxic activities of some medicinal polypore fungi from China. Fitoterapia. 77:408–410. 2006. View Article : Google Scholar : PubMed/NCBI

15 

Xu HL, Yu XF, Qu SC, Zhang R, Qu XR, Chen YP, Ma XY and Sui DY: Anti-proliferative effect of Juglone from Juglans mandshurica Maxim on human leukemia cell HL-60 by inducing apoptosis through the mitochondria-dependent pathway. Eur J Pharmacol. 645:14–22. 2010. View Article : Google Scholar : PubMed/NCBI

16 

Oldham ED, Nunes LM, Varela-Ramirez A, Rankin SE, Knutson BL, Aguilera RJ and Lehmler HJ: Cytotoxic activity of triazole-containing alkyl β-D-glucopyranosides on a human T-cell leukemia cell line. Chem Cent J. 9:32015. View Article : Google Scholar : PubMed/NCBI

17 

Zhang H, Xu HL, Fu WW, Xin Y, Li MW, Wang SJ, Yu XF and Sui DY: 20(S)-protopanaxadiol induces human breast cancer MCF-7 apoptosis through a caspase-mediated pathway. Asian Pac J Cancer Prev. 15:7919–7923. 2014. View Article : Google Scholar : PubMed/NCBI

18 

Chen W, Du J, Li X, Su J, Huang Y, Ding N, Zhang M and Jiang S: miR-509-3p promotes cisplatin-induced apoptosis in ovarian cancer cells through the regulation of anti-apoptotic genes. Pharmacogenomics. 18:1671–1682. 2017. View Article : Google Scholar : PubMed/NCBI

19 

Schorr GS, Falcone EA, Moretti DJ and Andrews RD: First long-term behavioral records from Cuvier's beaked whales (Ziphius cavirostris) reveal record-breaking dives. PLoS One. 9:e926332014. View Article : Google Scholar : PubMed/NCBI

20 

Deeb D, Gao X, Jiang H, Janic B, Arbab AS, Rojanasakul Y, Dulchavsky SA and Gautam SC: Oleanane triterpenoid CDDO-Me inhibits growth and induces apoptosis in prostate cancer cells through a ROS-dependent mechanism. Biochem Pharmacol. 79:350–360. 2010. View Article : Google Scholar : PubMed/NCBI

21 

Choi BH, Kim W, Wang QC, Kim DC, Tan SN, Yong JW, Kim KT and Yoon HS: Kinetin riboside preferentially induces apoptosis by modulating Bcl-2 family proteins and caspase-3 in cancer cells. Cancer Lett. 261:37–45. 2008. View Article : Google Scholar : PubMed/NCBI

22 

Hail N Jr, Carter BZ, Konopleva M and Andreeff M: Apoptosis effector mechanisms: A requiem performed in different keys. Apoptosis. 11:889–904. 2006. View Article : Google Scholar : PubMed/NCBI

23 

Aragane Y, Kulms D, Metze D, Wilkes G, Pöppelmann B, Luger TA and Schwarz T: Ultraviolet light induces apoptosis via direct activation of CD95 (Fas/APO-1) independently of its ligand CD95L. J Cell Biol. 140:171–182. 1998. View Article : Google Scholar : PubMed/NCBI

24 

Abraham MC and Shaham S: Death without caspases, caspases without death. Trends Cell Biol. 14:184–193. 2004. View Article : Google Scholar : PubMed/NCBI

25 

Salvesen GS and Dixit VM: Caspase activation: The induced-proximity model. Proc Natl Acad Sci USA. 96:10964–10967. 1999. View Article : Google Scholar : PubMed/NCBI

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Li X, Bau T and Bao H: FPOA induces apoptosis in HeLa human cervical cancer cells through a caspase‑mediated pathway. Oncol Lett 15: 8357-8362, 2018.
APA
Li, X., Bau, T., & Bao, H. (2018). FPOA induces apoptosis in HeLa human cervical cancer cells through a caspase‑mediated pathway. Oncology Letters, 15, 8357-8362. https://doi.org/10.3892/ol.2018.8380
MLA
Li, X., Bau, T., Bao, H."FPOA induces apoptosis in HeLa human cervical cancer cells through a caspase‑mediated pathway". Oncology Letters 15.6 (2018): 8357-8362.
Chicago
Li, X., Bau, T., Bao, H."FPOA induces apoptosis in HeLa human cervical cancer cells through a caspase‑mediated pathway". Oncology Letters 15, no. 6 (2018): 8357-8362. https://doi.org/10.3892/ol.2018.8380
Copy and paste a formatted citation
x
Spandidos Publications style
Li X, Bau T and Bao H: FPOA induces apoptosis in HeLa human cervical cancer cells through a caspase‑mediated pathway. Oncol Lett 15: 8357-8362, 2018.
APA
Li, X., Bau, T., & Bao, H. (2018). FPOA induces apoptosis in HeLa human cervical cancer cells through a caspase‑mediated pathway. Oncology Letters, 15, 8357-8362. https://doi.org/10.3892/ol.2018.8380
MLA
Li, X., Bau, T., Bao, H."FPOA induces apoptosis in HeLa human cervical cancer cells through a caspase‑mediated pathway". Oncology Letters 15.6 (2018): 8357-8362.
Chicago
Li, X., Bau, T., Bao, H."FPOA induces apoptosis in HeLa human cervical cancer cells through a caspase‑mediated pathway". Oncology Letters 15, no. 6 (2018): 8357-8362. https://doi.org/10.3892/ol.2018.8380
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team